GRCL Gracell Biotechnologies Inc. ADRs

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$3.20  -0.02 (-0.62%)
As of 10/03/2022 15:56:03 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  
IPO date:  01/08/2021
Outstanding shares:  67,674,125
Average volume:  80,961
Market cap:   $175,952,725
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BM90J85
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.13
PS ratio:   3,177.00
Return on equity:   -24.72%
Net income %:   -123,430.05%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy